Summary of Arcus Therapeutics Conference Call Company and Industry Overview - **Company**: Arcus Therapeutics - **Industry**: Oncology, specifically focusing on HIF-2 inhibitors for cancer treatment Key Points and Arguments Casdatifan vs. Belzutifan - **Differentiation**: Casdatifan is positioned as a best-in-class HIF-2 inhibitor compared to Merck's belzutifan, primarily due to its pharmacokinetic and pharmacodynamic (PK/PD) profile, which allows for more effective targeting of the cancer [2][6] - **Clinical Efficacy**: In late-line settings, casdatifan shows a primary progression rate of approximately 18% compared to belzutifan's nearly 35% [3] - **Response Rates**: The confirmed response rate for casdatifan is about 35% across 120 patients, with the 100 mg cohort showing a 45% response rate, significantly higher than belzutifan's over 20% [4] - **Progression-Free Survival (PFS)**: Median PFS for casdatifan is reported at 12.2 months, with the 100 mg cohort exceeding 15 months, while belzutifan shows around 5.6 months [4] Biomarker Data - **Erythropoietin Suppression**: Casdatifan demonstrates deeper and more durable suppression of erythropoietin production compared to belzutifan, which loses its pharmacodynamic effect after about 9 weeks [5] - **Correlation with Efficacy**: There is a clear correlation between the ability to suppress erythropoietin and clinical outcomes, reinforcing the efficacy of casdatifan [5] Treatment Durability - **Prolonged Disease Control**: Patients on casdatifan can experience prolonged disease control, with some remaining stable for over two years, indicating a non-toxic mechanism that allows the immune system to strengthen [10][11] - **Resistance Mechanism**: There is no known mechanism for resistance to HIF-2 inhibitors, which is a significant advantage over other cancer therapies [12] Clinical Development and Future Studies - **ARC-20 Study**: The study has added multiple cohorts to evaluate different dosing regimens and combinations, with a steady stream of data expected over the next two to three years [25] - **Upcoming Data**: Key datasets expected include the combination of casdatifan with cabozantinib and anti-PD-1 therapies, with initial results anticipated between July and October [26][30] Market Position and Strategy - **TKI Partner Selection**: Cabozantinib was chosen as the TKI partner due to its familiarity and better tolerability among clinicians compared to lenvatinib, which has more complex dosing [32][34] - **Regulatory Strategy**: The primary endpoint for the PEAK-1 study is PFS, which aligns with regulatory standards for second-line RCC treatments, and is expected to maximize the probability of success [43][44] Competitive Landscape - **Market Dynamics**: The use of HIF-2 inhibitors is expected to expand across multiple lines of therapy, potentially leading to a larger market opportunity compared to other tumor types where treatment options are limited [69] Additional Important Insights - **Anemia Management**: Anemia rates for casdatifan are comparable to belzutifan, with ongoing improvements in managing these side effects expected as clinical experience grows [21][23] - **Subsequent Therapy Considerations**: The geographic footprint for belzutifan usage is limited outside the U.S., which may not significantly impact the subsequent therapy landscape for casdatifan [53] This summary encapsulates the critical insights from the conference call regarding Arcus Therapeutics' strategic positioning, clinical data, and future outlook in the oncology market.

Core Insights - Arcus Biosciences aims to establish casdatifan as a "best-in-class" HIF-2α inhibitor for clear cell renal cell carcinoma (ccRCC) with updated clinical data showing promising efficacy compared to belzutifan [3][5][14] Clinical Data and Development - Updated analysis from the ARC-20 study indicates a median progression-free survival (PFS) of 15.1 months for casdatifan monotherapy, significantly longer than the 5.6-month PFS reported for belzutifan in similar late-line settings [1][2][5] - The confirmed overall response rate (ORR) for casdatifan has risen to 45% in the latest data [5] - The Phase III PEAK-1 trial is actively enrolling patients, comparing casdatifan plus cabozantinib against cabozantinib alone, with a goal to complete enrollment by year-end [6][10] Financial Overview - Arcus ended Q4 with $1.0 billion in cash, following a $288 million financing, and expects to fund operations into at least the second half of 2028 [4][17][18] - The company projects 2026 GAAP revenue between $45 million and $55 million, with anticipated decreases in operating expenses [18] Market Opportunity - The renal cell carcinoma (RCC) market is projected to exceed $10 billion annually, with expectations to grow to $13 billion by 2030, positioning casdatifan as a key player in this competitive landscape [14][15] - Arcus estimates peak sales for casdatifan could reach $2.5 billion in the IO-experienced setting and $3 billion or more in the first-line setting [15] Immunology Pipeline - Arcus is developing an inflammation and immunology (I&I) portfolio, with plans to enter clinical trials for a MRGPRX2 antagonist and a selective TNF receptor 1 inhibitor [16]

Financial Data and Key Metrics Changes - The company reported GAAP revenue of $33 million for Q4 2025, an increase from $26 million in Q3 2025, primarily driven by collaboration with Gilead [35] - Cash at the end of Q4 was $1 billion, up from $841 million at the end of Q3, bolstered by a $288 million financing in November [35][36] - R&D expenses decreased to $121 million in Q4 from $141 million in Q3, while G&A expenses slightly decreased from $27 million to $26 million [35] Business Line Data and Key Metrics Changes - The confirmed overall response rate (ORR) for the 100 mg cohort of casdatifan increased from 35% to 45%, with a median progression-free survival (PFS) of 15.1 months [16][18] - The pooled analysis ORR improved from 31% to 35%, significantly higher than belzutifan's observed rates [16][18] Market Data and Key Metrics Changes - The renal cell carcinoma (RCC) market is projected to grow from over $10 billion annually today to $13 billion by 2030, with casdatifan targeting a peak sales opportunity of $5 billion in first and second-line RCC settings [24][26] - The company aims to capture a substantial share of the IO-experienced setting, which includes approximately 21,000 patients in major markets, nearly double the third-line patient population where belzutifan is approved [26] Company Strategy and Development Direction - The company is focused on establishing casdatifan as the best-in-class HIF-2 inhibitor and the new standard of care for clear cell RCC, with a fast-to-market strategy for its Phase III study, PEAK-1 [4][8] - A TKI-free regimen is being developed for frontline therapy, which is expected to improve patient quality of life and treatment outcomes [10][11] - The immunology portfolio is also being expanded, with two programs expected to enter the clinic within the next 12 months [14][30] Management's Comments on Operating Environment and Future Outlook - Management emphasized the transformative potential of 2026 for the company, with multiple data presentations and advancements in clinical programs expected [4][39] - The company is confident in its ability to fund operations until at least the second half of 2028, with a significant decrease in operating expenses anticipated for 2026 [37][38] Other Important Information - The company is leveraging its ARC-20 study to drive development strategy for casdatifan, with a focus on demonstrating its best-in-class profile [12][22] - The upcoming ASCO GU presentation is expected to provide critical data that will reinforce the differentiation of casdatifan from belzutifan [7][39] Q&A Session Summary Question: What are the benchmarks for IO therapies as the company moves away from TKI-based regimens? - Management highlighted Ipi-Nivo as a key benchmark, noting its primary progression rate of 20%-25% and PFS of around 12 months, with the goal to demonstrate meaningful improvement with casdatifan [44][46] Question: What is the status of the volrustomig plus casdatifan study? - The study was paused but continues to provide valuable data, with no primary progression observed since dose adjustments [50][51] Question: How does the company view the upcoming LITESPARK-011 data from Merck? - Management expressed optimism that positive data from Merck would validate the field and drive enrollment for PEAK-1, with confidence in outperforming Merck's combination [65][66] Question: What is the impact of potential discontinuation of STAR-121 based on futility analysis? - Management indicated minimal operational impact as the study is fully enrolled, with a decrease in expenses expected in the latter stages of the trial [81][82]

Financial Data and Key Metrics Changes - The company reported GAAP revenue of $33 million for Q4 2025, an increase from $26 million in Q3 2025, primarily driven by collaboration with Gilead [35] - R&D expenses decreased to $121 million in Q4 2025 from $141 million in Q3 2025, while G&A expenses slightly decreased from $27 million to $26 million [35] - The cash position improved to $1 billion at the end of Q4 2025, up from $841 million at the end of Q3 2025, bolstered by a $288 million financing in November [35] Business Line Data and Key Metrics Changes - The confirmed overall response rate (ORR) for the 100 mg cohort of casdatifan increased from 35% to 45%, indicating significant efficacy improvement [16] - The median progression-free survival (PFS) for the 100 mg cohort was reported at 15.1 months, with a follow-up of 17.8 months, showcasing a strong performance compared to belzutifan [16][18] - The pooled analysis of casdatifan showed an ORR increase from 31% to 35%, further establishing its efficacy over belzutifan [16] Market Data and Key Metrics Changes - The renal cell carcinoma (RCC) market is projected to grow from over $10 billion annually today to $13 billion by 2030, with casdatifan targeting both late-line and early-line settings [24] - The company estimates a peak sales opportunity of $2.5 billion in the IO-experienced setting and potentially $3 billion or more in the first-line setting, indicating a substantial market opportunity [26] Company Strategy and Development Direction - The company aims to establish casdatifan as the best-in-class HIF-2 inhibitor and the new standard of care for clear cell RCC, focusing on a TKI-free regimen [4][8] - The first phase 3 study, PEAK-1, is actively enrolling and designed to establish casdatifan plus cabozantinib as the new standard of care in IO-experienced RCC [19] - The company is also exploring its immunology portfolio, with plans to advance two lead programs into the clinic by early next year [30] Management's Comments on Operating Environment and Future Outlook - Management emphasized that 2026 will be transformative for the company, with multiple data presentations and advancements in clinical programs expected [4] - The management expressed confidence in the differentiation of casdatifan compared to belzutifan, particularly in terms of safety and efficacy [7][8] - The company anticipates that the results from the upcoming ASCO GU presentations will validate their ongoing studies and drive enrollment in PEAK-1 [66] Other Important Information - The company plans to initiate a phase 3 study for casdatifan in the frontline setting by the end of 2026, contingent on safety and efficacy data [22] - The company owns nearly all rights to casdatifan, with revenues expected to accrue primarily to them, enhancing their financial outlook [27] Q&A Session Summary Question: What are the benchmarks for IO therapies as the company moves away from TKI-based regimens? - Management highlighted ipilimumab-nivolumab (ipi-nivo) as a key benchmark, noting its primary progression rate of 20%-25% and PFS of around 12 months [44] Question: What is the status of the volrustomig plus casdatifan study? - The study was paused but continues to provide valuable data, with no primary progression observed since dose adjustments [50] Question: How does the company view the upcoming LITESPARK-011 data from Merck? - Management expects positive data from LITESPARK-011 to validate the field and drive enrollment in their own studies, believing they can outperform Merck's combination [66]

Financial Data and Key Metrics Changes - The company reported GAAP revenue of $33 million for Q4 2025, an increase from $26 million in Q3 2025, primarily driven by collaboration with Gilead [34] - Cash at the end of Q4 was $1 billion, up from $841 million at the end of Q3, bolstered by a $288 million financing in November [34] - R&D expenses decreased to $121 million in Q4 from $141 million in Q3, while G&A expenses slightly decreased from $27 million to $26 million [34] Business Line Data and Key Metrics Changes - The confirmed overall response rate (ORR) for the 100 mg cohort of casdatifan increased from 35% to 45%, which is twice that observed with belzutifan [15] - The median progression-free survival (PFS) for the 100 mg cohort was reported at 15.1 months, significantly longer than the 5.6 months observed for belzutifan [16][17] Market Data and Key Metrics Changes - The renal cell carcinoma (RCC) market is projected to grow from over $10 billion annually today to $13 billion by 2030, with casdatifan targeting a peak sales opportunity of $5 billion in first and second-line RCC alone [22][25] - The company aims to capture a substantial share of the IO-experienced setting, which includes approximately 21,000 patients in major markets, nearly double the third-line patient population where belzutifan is currently approved [25] Company Strategy and Development Direction - The company is focused on establishing casdatifan as the best-in-class HIF-2 inhibitor and the new standard of care for clear cell renal cell carcinoma [4] - A fast-to-market strategy is being employed with the PEAK-1 study, which is actively enrolling and designed to establish CAS plus cabozantinib as the new standard of care in IO-experienced clear cell RCC [18] - The company is also developing a TKI-free regimen for frontline therapy, which is expected to improve patient quality of life and treatment outcomes [11][12] Management's Comments on Operating Environment and Future Outlook - Management emphasized that 2026 will be a transformative year for the company, with significant data presentations and advancements in the clinical program for casdatifan [4] - The management expressed confidence in the differentiation of casdatifan compared to belzutifan, particularly regarding safety and efficacy profiles [6][10] Other Important Information - The company plans to initiate a phase 3 study for casdatifan in the frontline setting by the end of 2026, contingent on safety and efficacy data [20] - The immunology portfolio is also being developed, with two programs expected to enter the clinic over the next 12 months [28] Q&A Session Summary Question: What trials are being looked at for IO benchmarks as the company moves away from TKI-based regimens? - Management indicated that ipilimumab-nivolumab (ipi-nivo) is a key focus, with a primary progression rate of 20%-25% and a PFS of around 12 months serving as benchmarks for improvement [42][43] Question: What is the status of the volrustomig plus casdatifan study? - The study was paused but continues to provide valuable data, with no primary progression observed since dose adjustments [49][50] Question: How do deeper EPO reductions correlate with responses in biomarker analyses? - There is a soft correlation between higher baseline EPO levels and the extent of reduction, indicating stronger HIF-2 activity in tumors [54][56] Question: What are the expectations for the LITESPARK-011 study? - Management expects good data from Merck's study, which will validate the field and potentially drive enrollment for the PEAK-1 study [64][65]

Full Year 2025 Investor Presentation Oncology and Immunology Portfolio Summary February 25, 2026 Forward-looking Statements/Safe Harbor Forward-Looking Statements Safe Harbor: This presentation contains forward-looking statements about Arcus Biosciences, Inc. ("we," "Arcus" or the "Company") made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements in this presentation that are not historical facts are forward-looking statements, including, without l ...

Core Viewpoint - Arcus Biosciences, Inc. (NYSE:RCUS) is experiencing mixed analyst ratings, with recent downgrades and upgrades reflecting uncertainty in its product differentiation and upcoming clinical data readouts [1][2]. Analyst Ratings - Wells Fargo downgraded Arcus Biosciences from Overweight to Equal Weight, lowering the price target from $30 to $23 due to unclear differentiation for Welireg and potential negative impacts from upcoming data readouts [1]. - Bank of America Securities maintained a Hold rating with a price target of $26 [2]. - Goldman Sachs upgraded the stock from Neutral to Buy, raising the price target from $16 to $28, highlighting the potential of the company's lead asset, casdatifan [2]. Product Development - Casdatifan is a selective HIF-2alpha inhibitor being developed for advanced clear cell renal cell carcinoma, with an estimated total addressable market of approximately 17,400 patients in the US/EU and projected risk-adjusted peak sales of about $1.7 billion [3]. - Phase 1 results for the ARC-20 trial showed overall response rates of 31% for the mono regimen and 46% for the combination regimen, with expectations for further improvement as the trial matures [3]. Company Overview - Arcus Biosciences is a clinical-stage biopharmaceutical company focused on developing and commercializing immunotherapies, competing in the biotechnology and pharmaceutical sectors [4].

Industry Overview - The global oncology market is undergoing rapid transformation due to increasing cancer incidence, demographic changes, and scientific advancements, with an estimated 2.1 million new cancer diagnoses and over 626,000 cancer-related deaths expected in the U.S. in 2026 [2] - Lifestyle-related risk factors and demographic shifts are contributing to a rise in cancer prevalence, leading to sustained growth in oncology healthcare spending [2] Innovation in Cancer Treatment - Advances in immunotherapies, targeted medicines, and personalized vaccines are reshaping cancer treatment, moving beyond traditional chemotherapy and radiation [3] - Immune-based approaches, such as checkpoint inhibitors and CAR-T therapies, utilize the immune system to target tumors, while targeted therapies focus on specific molecular and genetic disease drivers [3] - Technologies like genomic sequencing and AI are enhancing biomarker discovery and patient stratification, leading to earlier diagnoses and improved survival rates across various cancer types [4] Pharmaceutical Investment - Major pharmaceutical companies, including Novartis, AstraZeneca, and Pfizer, are investing heavily in oncology pipelines, developing new therapies such as antibody-drug conjugates and next-generation immuno-oncology treatments [5] - Smaller biotech firms are also crucial in driving innovation through partnerships, licensing deals, and acquisitions [5] Market Resilience - The oncology sector is viewed as one of the most resilient and attractive segments of the global healthcare market for long-term investors, supported by ongoing innovation and favorable reimbursement trends [6] Company Highlights - **ImmunityBio**: Its lead drug, Anktiva, approved in April 2024, generated $113 million in preliminary sales in 2025, with a 750% increase in volumes. The drug is under review in the EU and is being evaluated for expanded use in various cancers [8][9] - **Arcus Biosciences**: Developing casdatifan, a potential best-in-class HIF-2a inhibitor for treating clear cell renal cell carcinoma, with a market opportunity of over $5 billion. Multiple data readouts are expected in 2026 [10] - **Allogene Therapeutics**: Focused on genetically engineered T-cell therapies, with lead candidate cema-cel in a pivotal phase II study for large B-cell lymphoma. Another candidate, ALLO-316, shows early anti-tumor activity in advanced renal cell carcinoma [12][13]

Summary of Arcus Biosciences FY Conference Call Company Overview - **Company**: Arcus Biosciences (NYSE:RCUS) - **Founded**: Approximately 10 years ago with a focus on small molecule drug development, particularly in oncology and immunology [2][3] Key Points on Oncology Programs - **Current Portfolio**: Two late-stage oncology programs and an emerging immunology portfolio [2] - **Financial Position**: Well-capitalized with $1 billion in cash, expected to last until the second half of 2028, covering initial phase three readouts and early immunology program proof of concept [3] Casdatifan Program - **Target**: HIF-2, validated by Merck's Belzudafan, which has a run rate of $800 million annually in late-line settings [5] - **Clinical Data**: - Casdatifan shows a median progression-free survival (PFS) of over 12 months compared to 5.6 months for Belzudafan in late-line settings [9] - Casdatifan demonstrates deeper and more durable suppression of erythropoietin production than Belzudafan [8] - **Market Opportunity**: Estimated at $5 billion, with potential to become the standard of care in kidney cancer [7][22] - **Development Strategy**: - PEAK-1 study combines casdatifan with TKI cabozantinib, expected to enroll quickly [11] - Plans to establish a TKI-sparing regimen in the front line, addressing the high rate of primary progression associated with current treatments [12][35] Quemliclustat Program - **Focus**: Small molecule CD73 inhibitor for front-line pancreatic cancer, showing a median overall survival (OS) of approximately 16 months compared to 9-11 months for standard care [17] - **Market Potential**: Estimated at over $4 billion [18] Immunology Programs - **Focus**: Targeting validated settings with high commercial potential using small molecules [19] - **MRGPRX2 Antagonist**: Aiming to treat atopic skin diseases, expected to enter the clinic in 2026 [19] - **Selective TNF Receptor 1 Inhibitor**: Anticipated to enter the clinic by late 2026 or early 2027, addressing limitations of current TNF antibodies [20][22] Strategic Insights - **Partnerships**: Shift from leveraging partnerships for capital to focusing on clinical collaborations that enhance internal programs [29][30] - **Market Recognition**: The market for casdatifan is underappreciated, with potential for long-term patient treatment leading to significant revenue [45] Financial and Operational Outlook - **Cash Needs**: Recent disappointing results from the STAR-221 trial have extended cash runway into the second half of 2028 [41] - **Execution Focus**: Emphasis on executing the development strategy and maintaining a diverse portfolio to mitigate binary risks associated with drug development [25][46] Conclusion - **Differentiation**: Arcus Biosciences stands out due to its ability to run late-stage trials while maintaining a robust discovery pipeline, positioning itself competitively against larger biotech firms [46][47]

Arcus Biosciences J.P. Morgan Healthcare Conference 2026 Oncology and Immunology Portfolio January 14, 2026 Forward-looking Statements/Safe Harbor Forward-Looking Statements Safe Harbor: This presentation contains forward-looking statements about Arcus Biosciences, Inc. ("we," "Arcus" or the "Company") made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements in this presentation that are not historical facts are forward-looking statements, including ...